key: cord-0327028-ny2f7693
authors: Zhou, Biao; Zhou, Runhong; Chan, Jasper Fuk-Woo; Zeng, Jianwei; Zhang, Qi; Yuan, Shuofeng; Liu, Li; Robinot, Rémy; Shan, Sisi; Ge, Jiwan; Kwong, Hugo Yat-Hei; Zhou, Dongyan; Xu, Haoran; Chan, Chris Chung-Sing; Poon, Vincent Kwok-Man; Chu, Hin; Yue, Ming; Kwan, Ka-Yi; Chan, Chun-Yin; Liu, Na; Chan, Chris Chun-Yiu; Chik, Kenn Ka-Heng; Du, Zhenglong; Au, Ka-Kit; Huang, Haode; Man, Hiu-On; Cao, Jianli; Li, Cun; Wang, Ziyi; Zhou, Jie; Song, Youqiang; Yeung, Man-Lung; To, Kelvin Kai-Wang; Ho, David D.; Chakrabarti, Lisa A.; Wang, Xinquan; Zhang, Linqi; Yuen, Kwok-Yung; Chen, Zhiwei
title: SARS-CoV-2 hijacks neutralizing dimeric IgA for enhanced nasal infection and injury
date: 2021-10-06
journal: bioRxiv
DOI: 10.1101/2021.10.05.463282
sha: 3b0c515d275700f6db20449dcb5af66cb47e8a8c
doc_id: 327028
cord_uid: ny2f7693

Robust severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection in nasal turbinate (NT) accounts for high viral transmissibility, yet whether neutralizing IgA antibodies can control it remains unknown. Here, we evaluated receptor binding domain (RBD)-specific monomeric B8-mIgA1 and B8-mIgA2, and dimeric B8-dIgA1 and B8-dIgA2 against intranasal SARS-CoV-2 challenge in Syrian hamsters. These antibodies exhibited comparably potent neutralization against authentic virus by competing with human angiotensin converting enzyme-2 (ACE2) receptor for RBD binding. While reducing viruses in lungs, pre-exposure intranasal B8-dIgA1 or B8-dIgA2 led to 81-fold more infectious viruses and severer damage in NT than placebo. Virus-bound B8-dIgA1 and B8-dIgA2 could engage CD209 as an alternative receptor for entry into ACE2-negative cells and allowed viral cell-to-cell transmission. Cryo-EM revealed B8 as a class II neutralizing antibody binding trimeric RBDs in 3-up or 2-up/1-down conformation. Therefore, RBD-specific neutralizing dIgA engages an unexpected action for enhanced SARS-CoV-2 nasal infection and injury in Syrian hamsters.

To isolate human monoclonal antibodies (MAbs), we obtained peripheral blood mononuclear 123 cells (PBMCs) from one acute (P4) and three convalescent (P1-P3) COVID-19 patients in 124 Hong Kong at a mean 73.5 (+25) days after symptoms onset (Supplementary Table 1) . 125

Enzyme-linked immunosorbent assay (ELISA) and pseudovirus neutralization assays 126 revealed that all patient sera showed SARS-CoV-2 RBD-and spike-specific binding (Fig. 1A  127 and 1B) and neutralizing antibody (NAb) activities (Fig. 1C) . The mean NAb IC 50 To determine the antiviral activities of these 18 RBD-specific human MAbs, we performed 146 binding and neutralization assays. Five of them, namely A6-IgG1, B4-IgG1, B7-IgG1, B8-147 IgG1 and C5-IgG1 displayed RBD-and spike-specific binding by ELISA (Fig. 1F) and 148 neutralizing activities against both pseudotyped and authentic viruses ( Fig. 1G and 149 Supplementary Fig. 1D) . Interestingly, the four most potent HuNAbs, B4-IgG1, B7-IgG1, 150 B8-IgG1 and C5-IgG1, all came from patient P3 ( Supplementary Fig. 1D ). Sequence 151 analysis revealed strong similarities between B7-, B8-, and C5-IgG1, which all contained an 152 IGHV1-69 heavy chain gene and an IGKV3 kappa light chain gene. B4-IgG1 contained 153 distinct IGHV3-66 and IGKV1-33 genes with CDR3 lengths of 12 amino acids (aa) and 9 aa, 154 and somatic hypermutation (SHM) rate of 3.8% and 4.6%, respectively (Supplementary 155 Table 2 ). B7 and B8 were the most similar, as both contained IGHV1-69 and IGKV3-11 156 though B8 had a shorter CDR3 (14 aa vs 18 aa) and higher SHM (4.8% vs 0.0%) than those 157 of B7 in the heavy chain. In the L chain, B7 and B8 shared a 9 aa CDR3, but B8 had a higher 158 SHM rate than that of B7 (1.7% vs 0.7%) C5-IgG1 had a similar IGHV1-69 light chain gene 159 with a 16 aa CDR3 and 2.4% SHM, but a different IGKV3-20 with a 9 aa CDR3 and 2.8% 160 SHM. By ELISA, these four P3-derived HuNAbs bound to the SARS-CoV-2 RBD with 161 half-maximal effective concentration (EC 50 ) values ranging from 0.02 to 0.06 µg/ml, 162 indicating stronger binding than that of the P4-derived A6-IgG1 (0.3 µg/ml) (Fig. 1F, left and  163 Supplementary these HuNAbs could compete with ACE2 for RBD binding by surface plasmon resonance 172 (SPR). We found that all of them strongly competed with ACE2 ( Level-3 (BSL-3) animal laboratory ( Fig. 2A) . In the pre-exposure prophylaxis group (G1, n 188 = 4), each hamster received a single intraperitoneal injection of 1.5 mg/kg B8-IgG1. In the 189 post-exposure treatment groups, each hamster received a single intraperitoneal injection of 190 1.5 mg/kg B8-IgG1 at day 1 (G2, n = 4), day 2 (G3, n = 4) or day 3 (G4, n = 4) postinfection 191 (dpi), respectively ( Fig. 2A) . The challenge dose was 10 5 plaque-forming units (PFU) of live 192 SARS-CoV-2 (HKU-001a strain) 47,48 . Another group of hamsters (G0, n = 4) received PBS 193 injection as a no-treatment control. One G4 animal died accidentally during the procedure. We found that infectious virus, measured by PFU, weas readily detected in all tissue 204 compartments of G0 hamsters but not in the lungs of 75% G1, 100% G2, 75% G3 and 0% G4 205 animals, nor in the NT of 50% G1, 75% G2, 50% G3 and 25% G4 animals ( Fig. 2B and 2E) . 206

The decrease in PFU was of 2-3 orders of magnitude, suggesting efficient viral suppression in 207 the lungs for the G1, G2, and G3 groups. A sensitive RT-PCR assay further demonstrated that 208 viral RNA copy numbers were decreased in the lungs by 3 orders of magnitude in 50% of G1 209 hamsters (Fig. 2C ). In contrast, there was no significant viral RNA reduction in the NT of G1 210 animals ( Fig. 2F) , suggesting lower efficacy of B8-IgG1 to prevent viral entry in the URT 211 than in the lungs. There were slight but not significant viral RNA load decreases in both 212 lungs and NT of G2 and some G3 animals. We then evaluated the number of infected cells or 213 foci in these two tissue compartments by anti-NP antibody staining. A clear decrease of NP-214 positive cells or foci was observed in the lungs of G1 and G2 hamsters (Fig. 2D ). Abundant 215 NP-positive cells with a diffuse distribution, however, were readily detected in the NT of all 216 the challenged hamsters (Fig. 2G) . These results demonstrated that systemic B8-IgG1 217 injection was effective at reducing productive SARS-CoV-2 infection in the lungs when used 218 for pre-exposure prophylaxis and early treatment especially within 48 hours post infection, 219 but was insufficient to prevent viral infection in the NT. 220

To determine the correlates of B8-IgG1-mediated protection, we also measured the antibody 222 concentration in serum, lung homogenate and NT homogenates at 0 and 4 dpi for all 223 experimental animals. On average, 4,257 ng/ml and 2,101 ng/ml B8-IgG1 were found in 224 animal sera at 0 and 4 dpi (Supplementary Table 6 Table 8 ). That said, B8-mIgA2 and B8-dIgA2 showed slightly more potent IC 90 activities 246 than B8-IgG1 in the pseudovirus neutralization assay using 293T-ACE2 cells as targets 247 (Supplementary Table 8 ). After introducing J chain, the proper dimer formation of B8-dIgA1 248 and B8-dIgA2 was confirmed by size exclusion chromatography analysis ( Supplementary Fig.  249 3E-F). Furthermore, B8-mIgA1, B8-mIgA2, B8-dIgA1 and B8-dIgA2 also retained 250 comparable competition with ACE2 for binding to spike by SPR analysis (Supplementary Fig.  251 3G-J). Therefore, the engineered IgA had the expected structural properties, and showed 252 antiviral activities as potent as those of B8-IgG1 in vitro. 253

We then evaluated the monomeric B8-mIgA1 and B8-mIgA2 in the hamster model, using a 254 higher 4.5 mg/kg dose via either intranasal or intraperitoneal injection, and used the same 255 amount of intranasal B8-IgG1 inoculation as a control (Fig. 3A to 3I) . Interestingly, while 256 changes in total RdRp and subgenomic sgNP viral RNA loads were not obvious ( Fig. 3D to 257 3E), B8-IgG1 and B8-mIgA1 (both i.n. and i.p.), but not B8-mIgA2, were able to 258 significantly suppress infectious virus production (PFU) in the lungs of 75% infected 259 hamsters by 2 orders of magnitude (Fig. 3D ). Sporadic infected cell foci were still detected in 260 the lung sections by anti-NP staining ( Fig. 4E and Supplementary Fig. 4A ), suggesting that 261 protection conferred by B8-IgG1 and B8-mIgA1 was not complete. B8-mIgA2 was not able 262 to suppress viral RNA load nor PFU in the challenged hamsters, regardless of the route of 263 antibody injection. On the other hand, like B8-IgG1, both B8-mIgA1 and B8-mIgA2 did not 264 achieve significant viral suppression in the NT. After intranasal administration of either B8-265 mIgA1 or B8-mIgA2, some hamsters even showed a trend of slightly increased infectious 266 virus production in NT, though this did not reach statistical significance ( Fig. 3F-3H ). Among 267 these animals, the NP-positive cells were detected readily in the NT, as demonstrated by the 268 whole section scanning, indicating the comparable distribution compared with the B8-IgG1 269 and no-treatment groups (Fig. 3I) . These results were consistent with many NP-positive cells 270 observed in diffusely infected areas of NT by classic IF (Supplementary Fig. 4B ). These 271 results demonstrated that B8-mIgA1 was more potent than B8-mIgA2 at limiting SARS-272

CoV-2 infection in the lungs, but that both mIgA did not prevent nor significantly limit Next, we tested the effects of dimeric B8-dIgA1 and B8-dIgA2 in Syrian hamsters. To 278 improve protective efficacy of intranasal dIgA treatment, we included a 3-fold higher dosage 279 group of 13.5 mg/kg besides the 4.5 mg/kg group (Fig. 4A to 4I), and we shortened the 280 interval between dIgA and virus inoculation to 12 hours (Fig. 4A ). Both RdRp and sgNP viral 281 RNA loads dropped significantly in the lungs of hamsters that received the high dose of B8-282 dIgA2 compared to the no-treatment group ( Fig. 4B and 4C ). Both B8-dIgA1 and B8-dIgA2 283 at the high dose also suppressed infectious viruses (PFU) in the lungs of 75% and 100% 284 treated hamsters, respectively (Fig. 4D ). High dose B8-dIgA1 and B8-dIgA2 also decreased 285 the number of NP-positive cells or foci in the lungs, with a more marked change for B8-286 dIgA2 ( Fig. 4E and Supplementary Fig. 5A ). Unexpectedly, however, we observed 287 significantly enhanced SARS-CoV-2 nasal infection and tissue damage in most infected 288 hamsters included the low and high dose groups of both B8-dIgA1 and B8-dIgA2, in all the 289 four assays used ( Fig. 4F to 4I ). High dose administration of B8-dIgA1 or B8-dIgA2 resulted 290 in increased PFU production in the NT by 37-fold and 81-fold, respectively, compared to the 291 no-treatment group (Fig. 4H ). Since our model showed comparable NT PFU on day 2 and 292 day 4 as described previously 48 , this level of enhanced infection was unusual. It was also not 293 observed with B8-IgG1 or monomeric B8-mIgA1 and B8-mIgA2 treatment, as described 294 above. Moreover, the distribution of NP-positive cells in hamsters treated with dimeric B8-295

IgA was broader and reached deeper into NT tissue compared to the no-treatment group, as 296 shown by whole section scanning ( Fig. 4I and Supplementary Fig. 5B ), which was associated 297 with more severe and extensive epithelium desquamation and luminal cell debris 298 ( Supplementary Fig. 5C ). The density of nasal NP + cells was also significantly higher in B8-299 dIgA2-treated hamsters than in PBS-treated animals (Supplementary Fig. 5D -E). It is 300 therefore conceivable that treatment with dimeric B8-IgA expanded the type and distribution 301 of target cells in the nasal epithelium. Critically, we confirmed that control dimeric dIgA1 302 and dIgA2 did not enhance SARS-CoV-2 infection under the same experimental conditions 303 ( Supplementary Fig. 6 ). These results demonstrated that, instead of inducing viral 304 suppression, pre-exposure dimeric B8-dIgA1 and B8-dIgA2 enhanced SARS-CoV-2 nasal 305 infection and injury significantly in Syrian hamsters, which was consistently found in three 306 independent experiments. 307

To validate the role of B8-dIgA1 and B8-dIgA2, we then measured B8-IgA concentrations in 308 the serum at day 0 and 4 dpi, and in the lung and NT homogenates at 4 dpi. B8-dIgA1 and 309 B8-dIgA2 were primarily detected in lung homogenates at 4 dpi and were apparently 310 undetectable in the serum and NT homogenates (Supplementary Table 9 ). The enhanced 311 viral replication in NT probably exhausted B8-dIgA1 and B8-dIgA2 locally, through 312 antibody-virus complex formation and clearance 30 . To address this possibility, we treated 313 separately five groups of naïve Syrian hamsters (n=4 per group) with each antibody at the 4.5 314 mg/kg dose. Twelve hours after the inoculation, antibody concentrations were readily 315 detected in each tissues compartment (Supplementary Table 10 Since B8 antibodies share the same binding site to the RBD domain, we sought to investigate 324 possible mechanisms of B8-dIgA1-and B8-dIgA2-enhanced infection. First, we consistently 325 found that 10 ng/ml B8-dIgA1 or B8-dIgA2 completely neutralized SARS-CoV-2 infection 326 in human renal proximal tubule cells (HK-2), as measured in our previously reported 327 immunofluorescence assay ( Supplementary Fig. 7 ) 49 . We also tested B8-mIgA2 and B8-328 dIgA2 neutralizing capacity in the MucilAir TM model, consisting of a reconstructed human 329 nasal epithelium, which contained goblet, ciliated, and basal cells ( indicating that these CD209 + cells were likely permissive to SARS-CoV-2 infection. We then 348 determined whether B8-dIgA1 and B8-dIgA2 could enhance SARS-CoV-2 infection in 293T 349 cells expressing human CD209 or CD299 but not ACE2. Using a low MOI of 0.05, we found 350 that pre-incubation of B8-dIgA1 and B8-dIgA2 enhanced live SARS-CoV-2 infection 351 significantly in 293T cells expressing human CD209, as determined by increased viral NP 352 production ( Fig. 5C ). Interestingly, human CD299, a type II integral membrane protein that 353 is 77% identical to CD209, did not show similar activities in the same experiment (Fig. 5C ). 354

Control dIgA1 and dIgA2 did not show any enhancement in NP + cell detection compared 355 with virus only. Considering that CD209 + DCs promote HIV-1 transmission to CD4 + T cells 356 via cell-cell contacts, we speculated that B8-dIgA1 and B8-dIgA2 might not be able to block 357 the similar process for SARS-CoV-2. Indeed, by testing the B8 antibodies at concentrations 358 100-times higher than IC 90 neutralization values (around 3000 ng/ml), none of B8-IgG1, B8-359 mIgA1, B8-mIgA2, B8-dIgA1 and B8-dIgA2 could block cell-cell fusion (Fig. 5D ). Taken 

To understand the potential mechanism of action of B8 HuNAb, we performed a cryo-EM 367 single-particle analysis of B8 Fab bound to the SARS-CoV-2 spike ectodomain trimer 368 ( Supplementary Fig. 8 ). Two B8-spike complex structures were determined based on 351,095 369 and 616,799 particles collected, respectively (Supplementary Table 11 ). One structure at 2.67 370 Å resolution contained the spike with all three RBDs adopting the "up" conformation (3u), 371

where each "up" RBD was bound by one B8 Fab ( Fig. 6A-B ). The other structure at 2.65 Å 372 resolution contained one spike trimer with 2 RBDs in the "up" conformation and 1 RBD in 373 the "down" conformation (2u1d), where each RBD was also bound by one B8 Fab despite the 374 presence of two distinct RBD conformations ( Fig. 6C -D). After superimposing the "3u" and 375 "2u1d" spikes, a ~53-degree rotation was observed between the "up" RBD (red color) in the 376 3u spike trimer and the "down" RBD (gray) in the 2u1d spike trimer (Fig. 6E ). The B8 Fab 377 appeared to bind to the receptor-binding motif (RBM) of the RBD through its heavy chain for 378 most of the interactions (Fig. 6F-G) . Therefore, the cellular receptor ACE2 would clash with 379 the B8 Fab due to the overlap of their respective epitopes on the RBM (Fig. 6F -H and 380

Supplementary Table 12 ). The elucidation of the epitope revealed that B8 could be grouped 381 into the SARS-CoV-2 neutralizing antibody class II 53 . These structural findings were further 382 supported by neutralization assays using a panel of pseudoviruses containing naturally 383 occurring mutations. Indeed, the E484K mutation from the South African SA 9 strain, 384 which is located within the B8-binding interface, caused a major loss of neutralizing potency 385

for all the B8 isotypes tested: IgG1, mIgA1, mIgA2, dIgA1 and dIgA2 (Supplementary Table  386 13). The comparable neutralization profiles of these NAbs against the full panel of viral 387 variants also indicated that the conformation of key RBD-binding residues remained 388 unchanged after engineering of the constant regions of these B8 isotypes. 

Single memory B cells isolated from PBMCs of infected patients were cloned as previously 571 described 76 . Briefly, one-step RT-PCR was performed on sorted single memory B cell with a 572 gene specific primer mix, followed by nested PCR amplifications and sequencing using the 573 heavy chain and light chain specific primers. Cloning PCR was then performed using heavy 574 chain and light chain specific primers containing specific restriction enzyme cutting sites 575 (heavy chain, 5′-AgeI/3′-SalI; kappa chain, 5′-AgeI/3′-BsiWI). The PCR products were 576 purified and cloned into the backbone of antibody expression vectors containing the constant 577 regions of human Igγ1 or Igα1 and Igα2. The Igα1 and Igα2 vectors were purchased from 578 InvivoGen (pfusess-hcha1 for IgA1 and pfusess-hcha2m1 for IgA2). The constructed 579 plasmids containing paired heavy and light chain expression cassettes were co-transfected 580 into 293T cells (ATCC) grown in 6-well plates. Antigen-specific ELISA and pseudovirus-581 based neutralization assays were used to analyze the binding capacity to SARS-CoV-2 RBD 582 and the neutralization capacity of transfected culture supernatants, respectively. 583 584 Genetic analysis of the BCR repertoire 585

Heavy chain and light chain germline assignment, framework region annotation, 586 determination of somatic hypermutation (SHM) levels (in nucleotides) and CDR loop lengths 587 (in amino acids) were performed with the aid of the IMGT/HighV-QUEST software tool 588 suite (www.imgt.org/HighV-QUEST). Sequences were aligned using Clustal W in the 589 BioEdit sequence analysis package (Version 7.2). Antibody clonotypes were defined as a set 590 of sequences that share genetic V and J regions as well as an identical CDR3. 591 592 Antibody production and purification 593

The paired antibody VH/VL chains were cloned into Igγ, Igα1 or Igα2 and Ig݇ expression 594 vectors using T4 ligase (NEB). For production of IgG and monomeric IgA, the plasmids with 595 paired heavy chain (IgG, IgA1, IgA2) and light chain genes were co-transfected into 596 Expi293 TM expression system (Thermo Fisher Scientific) following the manufacturer's 597 protocol to produce recombinant monoclonal antibodies. For dIgA antibody production, 598 plasmids of paired heavy chain (IgA1, IgA2) and kappa light chain together with a J chain 599 were co-transfected into Expi293 TM expression system (Thermo Fisher Scientific) at the ratio 600 of 1:1:1 following the manufacturer's instructions. Antibodies produced from cell culture 601 supernatants were purified immediately by affinity chromatography using recombinant 602 

The neutralizing activity of NAbs was determined using a pseudotype-based neutralization 620 assay as we previously described 77 s  u  b  j  e  c  t  e  d  t  o  3  D  a  u  t  o   -refinement,   y  i  e  l  d  i  n  g  f  i  n  a  l   724   r  e  s  o  l  u  t  i  o  n  s  a  t  3  .  2  1  A   a  n  d  3  .  0 6 A , respectively. Further CTF refinement and Bayesian 725 polishing improved the resolution to 2.65 Å (2u1d, C1 symmetry) and 2.67 Å (3u, C3 726 symmetry) with better map quality. To improve the RBD-B8 portion map density, focused 727 local search classification was applied for each RBD-B8 portion with an adapted soft mask. 728

The best classes for each RBD-Fab portion were selected and yielded a final resolution at 729 3.56 Å (RBD-Fab1, up) 

Genomic characterization of the 2019 novel human-pathogenic 930 coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan

Bat-to-human: spike features determining 'host jump' 933 of coronaviruses SARS-CoV, MERS-CoV, and beyond

Cell entry mechanisms of SARS-CoV-2

Mechanisms of 938 coronavirus cell entry mediated by the viral spike protein

Structural and Functional Basis of SARS-CoV-2 Entry by Using 941

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and 943 Is Blocked by a Clinically Proven Protease Inhibitor

Structure of the SARS-CoV-2 spike receptor-binding domain bound to 946 the ACE2 receptor

Structure, Function, and Antigenicity of the SARS-CoV-2 Spike 948

Structural basis for the recognition of SARS-CoV-2 by full-length 950 human ACE2

Genomic characterisation and epidemiology of 2019 novel coronavirus: 952 implications for virus origins and receptor binding

A new coronavirus associated with human respiratory disease in China. 955

Severe acute respiratory 960 syndrome coronavirus as an agent of emerging and reemerging infection

Transmission of 2019-nCoV Infection from an Asymptomatic Contact 963 in Germany

First Case of 2019 Novel Coronavirus in the United States

A familial cluster of pneumonia associated with the 2019 novel 967 coronavirus indicating person-to-person transmission: a study of a family cluster

Clinical Characteristics of 138 Hospitalized Patients With

Loss of furin cleavage site attenuates SARS-CoV-2 pathogenesis. 973

Natural transmission of bat-like SARS-CoV-2PRRA variants in 975 COVID-19 patients

Host and viral determinants for efficient SARS-CoV-2 infection of the 977 human lung

D614G Mutation Alters SARS-CoV-2 Spike Conformation and 979 Enhances Protease Cleavage at the S1/S2 Junction

Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G 982 Increases Infectivity of the COVID-19 Virus

Spike mutation D614G alters SARS-CoV-2 fitness

SARS-CoV-2 shedding and seroconversion among passengers 987 quarantined after disembarking a cruise ship: a case series

Improved Molecular Diagnosis of COVID-19 by the Novel, Highly 990 Sensitive and Specific COVID-19

Assay Validated In Vitro and with Clinical Specimens

Temporal profiles of viral load in posterior oropharyngeal saliva 994 samples and serum antibody responses during infection by SARS-CoV-2: an 995 observational cohort study

A perspective on potential antibody-dependent enhancement of 998 SARS-CoV-2

A human neutralizing antibody targets the receptor-binding site of 1000 SARS-CoV-2

Potently neutralizing and protective human antibodies against SARS-1002

Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 1004 spike

Potent Neutralizing Antibodies against SARS-CoV-2 Identified by 1006

Single-Cell Sequencing of Convalescent Patients' B Cells

Convergent antibody responses to SARS-CoV-2 in convalescent 1009 individuals

Potent neutralization of SARS-CoV-2 by human antibody heavy-chain 1011 variable domains isolated from a large library with a new stable scaffold

A noncompeting pair of human neutralizing antibodies block COVID-19 1014 virus binding to its receptor ACE2

Identification of Human Single-Domain Antibodies against SARS-CoV-1017

Lung mucosal 1019 immunity: immunoglobulin-A revisited

Multi-faceted functions of secretory IgA at mucosal surfaces. Front 1022 Immunol 4

A cross-reactive human IgA monoclonal antibody blocks SARS-1024

CoV-2 spike-ACE2 interaction

IgA dominates the early neutralizing antibody response to SARS-1027

Dimeric IgA is a specific biomarker of recent SARS-CoV-2 1029 infection. medRxiv

In Nasal Mucosal Secretions, Distinct IFN and IgA 1032 Responses Are Found in Severe and Mild SARS-CoV-2 Infection

Distinct systemic and mucosal immune responses during acute SARS-1035

CoV-2 infection

Enhanced SARS-CoV-2 neutralization by dimeric IgA

Robust SARS-CoV-2 infection in nasal turbinates after treatment with 1039 systemic neutralizing antibodies

Simulation of the clinical and pathological manifestations of 1042

COVID-19) in golden Syrian hamster model: implications 1043 for disease pathogenesis and transmissibility

Soluble ACE2-mediated cell entry of SARS-CoV-2 via interaction 1046 with proteins related to the renin-angiotensin system

SARS-CoV-2 infection induces the dedifferentiation of multiciliated 1049 cells and impairs mucociliary clearance

Spatiotemporal interplay of severe acute respiratory syndrome 1052 coronavirus and respiratory mucosal cells drives viral dissemination in rhesus 1053 macaques

Recognition of secretory IgA by DC-SIGN: 1055 implications for immune surveillance in the intestine

Analysis of SARS-CoV-2 variant mutations reveals neutralization 1058 escape mechanisms and the ability to use ACE2 receptors from additional species

COVID-19 antibody therapeutics tracker: a global online database of 1061 antibody therapeutics for the prevention and treatment of COVID-19

Anti-HIV IgA isotypes: differential virion capture and inhibition 1064 of transcytosis are linked to prevention of mucosal R5 SHIV transmission

Free secretory component and other proteins in human lung 1067 lavage

PET/CT targeted tissue sampling reveals virus specific dIgA can 1069 alter the distribution and localization of HIV after rectal exposure

The Human Immune Response to Dengue Virus Is Dominated 1072 by Highly Cross-Reactive Antibodies Endowed with Neutralizing and Enhancing 1073

Antibody fucosylation predicts disease severity in secondary 1075 dengue infection

Antibody Effector Functions During Respiratory Syncytial Virus Infection and 1078 Disease

Molecular Mechanism for Antibody-Dependent Enhancement of 1080

Anti-spike IgG causes severe acute lung injury by skewing macrophage 1082 responses during acute SARS-CoV infection

Prospects for a safe COVID-19 vaccine

Afucosylated IgG characterizes enveloped viral responses and 1087 correlates with COVID-19 severity

REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in 1089 rhesus macaques and hamsters

An infectivity-enhancing site on the SARS-CoV-2 spike protein targeted 1092 by antibodies

The N-terminal domain of spike glycoprotein mediates SARS-CoV-1094 2 infection by associating with L-SIGN and DC-SIGN. bioRxiv

DC-SIGN, a dendritic cell-specific HIV-1-binding protein 1097 that enhances trans-infection of T cells

Mechanisms for Cell-to-Cell 1100 Transmission of HIV-1. Front Immunol 9

Attenuated Interferon and Proinflammatory Response in SARS-CoV-1103 2-Infected Human Dendritic Cells Is Associated With Viral Antagonism of STAT1 1104

DC/L-SIGN recognition of spike glycoprotein promotes SARS-1106

CoV-2 trans-infection and can be inhibited by a glycomimetic antagonist

Analysis of plasmacytoid and myeloid dendritic cells in nasal 1109 epithelium

Nasal ciliated cells are primary targets for SARS-CoV-2 replication 1111 in the early stage of COVID-19

SARS-CoV-2 vaccines in development

Key gp120 Glycans Pose Roadblocks to the Rapid Development of 1116 VRC01-Class Antibodies in an HIV-1-Infected Chinese Donor

Rapid generation of fully human monoclonal antibodies specific to a 1119 vaccinating antigen

Cancellation of 1121 elective surgery and intensive care unit capacity in New York state: a retrospective 1122 cohort analysis

Comparative tropism, replication kinetics, and cell damage profiling of 1125 SARS-CoV-2 and SARS-CoV with implications for clinical manifestations

The relative viral RdRp RNA copy numbers (normalized to β-actin) were determined by 1224 RT-PCR in NT homogenates

The relative viral sgNP RNA copies (normalized to β-actin) were determined by RT-1226 PCR in NT homogenates

Infectious virus (PFU) was measured in NT homogenates by the viral plaque assay in 1228

Representative NT images of infected animals by scanning whole tissue section. The 1230 signal of SARS-CoV-2 NP was shown in bright spots

Log-transformed units are shown in (B) to (H) except in (E)

B8-dIgA1 and B8-dIgA2 enhance SARS-CoV-2 infection via CD209

The effects of B8-dIgA2 on SARS-CoV-2 infection in the MucilAir TM model

1000 ng/ml, respectively, in the apical compartment with 1238 or without mucus for 1 hour

BetaCoV/France/IDF00372/2020) for 4 hours. The viral RNA loads were measured by RT-1240

PCR in both the apical and basal compartments and are shown in log-transformed units

Representative confocal images (400×) of olfactory epithelium in NT showed the 1242 expression of CD209 (DC-SIGN) in green and ACE2 in magenta by immunohistochemical 1243 staining of experimental hamsters treated with B8-dIgA2 without (left) or with (middle and 1244 right) SARS-CoV-2 infection. Color-coding indicates specific antibodies used for double 1245 staining

The CD209 or CD299 overexpressed-HEK 293T cells were pre-treated for 6 hours with 1247

Two days after infection, SARS-CoV-2 NP 1249 expression (green) was quantified by the mean fluorescence intensity (MFI) after anti-NP IF 1250 staining

The effects of B8 antibodies on cell-cell fusion

CoV-2 spike and GFP were pre-treated with 100× the IC 90 dose of B8-IgG1, B8-mIgA1

B8-dIgA1, B8-dIgA2 or and IgG isotypic control for 1 hour, respectively. Vero-E6

cells transfected with TMPRSS2 were then added to the treated 293T-spike-GFP cells and 1255